Project Grant K99CA302523
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$170K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award of $216,972 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to understand and target vulnerabilities governing the G1/S transition and replication stress in small cell lung cancer (SCLC). The key objectives are to: 1) determine the mechanistic underpinnings of increased replication stress in SCLC, including the role of low LMNA levels and R-loops, and develop therapeutic approaches targeting...
This $548,915 five-year Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) supports research to elucidate a novel tumor suppressive axis involving the stress activated protein kinase (SAPK) pathway in small cell lung cancer (SCLC). The research aims to leverage cellular models, genetically engineered mouse models, and human tumor datasets to define the biological roles of the SAPK/AP-1 pathway in SCLC tumor suppression. Key objectives...
This Project Grant award of $230,010 from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to unravel the cellular and molecular drivers behind the aggressive metastasis of small cell lung cancer (SCLC). The award was granted to the University of Chicago and will run from March 1, 2025 to February 28, 2027. The research integrates human pluripotent stem cell-derived SCLC models, clinical samples, and patient-derived...
This $844,231 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) to target the POU2F3 protein in small cell lung cancer. The two-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will enable Moffitt Cancer Center to conduct dual up- and downstream targeting of POU2F3, a...
This $3,787,956.00 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by New York University School of Medicine to investigate and target replication stress in small cell lung cancer (SCLC). The research aims to: 1) understand how the SLFN11 gene impacts chemotherapy response in SCLC subtypes, 2) study how replication stress response pathways and modulators regulate chemosensitivity, and 3) develop strategies to target replication...
The National Cancer Institute (NCI) awarded a $701,538 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research on understanding the evolution and maintenance of distinct epigenomic subtypes of small cell lung cancer (SCLC), a highly aggressive lung cancer subtype. The project aims to elucidate the mechanistic roles of lineage factors, particularly NKX2-1, in the development and adaptation of...
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $191,675.00 to The University of Texas Southwestern Medical Center to conduct research on innovative therapeutic strategies for small cell lung cancer (SCLC). The research aims to investigate the role of Jumonji demethylases as potential druggable targets in SCLC, including evaluating the impact of Jumonji inhibitors on SCLC growth and therapeutic resistance. The project will...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $158,365 to the University of North Carolina at Chapel Hill to study the effects of NRF2 signaling on the development of lung squamous cell carcinoma (LUSC). The research aims to understand how NRF2 activation impacts LUSC initiation, progression, and the tumor microenvironment using a novel genetically-engineered mouse model. The University of Washington will perform multi-omics...
This Project Grant award of $631,156 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to uncover the core mechanisms driving lineage plasticity (LP) in EGFR-mutant lung adenocarcinoma (LUAD). The research aims to systematically define the epigenetic, transcriptional, and signaling alterations that facilitate the transformation of LUAD to the more aggressive small cell lung cancer (SCLC) subtype, a lethal mechanism...